Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Two-part, Open-label Dose-escalation and Double-blind, Placebo-controlled Dose-expansion Study With an Open-label Extension to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis

NCT03283826 is registered in ClinicalTrials.gov with Atara Biotherapeutics as lead sponsor.

NCT NCT03283826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03283826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Two-part, Open-label Dose-escalation and Double-blind, Placebo-controlled Dose-expansion Study With an Open-label Extension to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
Lead sponsor
Atara Biotherapeutics
Phase
Phase 1/2
Overall status
Terminated
Start date
October 19, 2017
Completion date
January 17, 2024
Enrollment
134 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

primary progressive multiple sclerosis, secondary progressive multiple sclerosis